Overview of Longatin

Quick Facts

Property	Description
Active ingredient	Noscapine (C22H23NO7)
Common form	Tablet, Syrup, Solution
Pharmacological class	Non-narcotic Antitussive (Cough suppressant)
Common use	Symptomatic relief of dry, nonproductive cough
Origin	Naturally occurring isoquinoline alkaloid (derived from opium)

What is Longatin and How is it Classified?

Longatin is a pharmaceutical preparation whose sole active component is Noscapine, a compound primarily classified as a non-narcotic antitussive. Noscapine is an isoquinoline alkaloid naturally occurring within the opium poppy, which establishes its origin as a derivative substance. Noscapine is recognized for its use as an antitussive for dry cough. This classification relates to the medicine's primary role in reducing the severity of coughing fits. This specific C22H23NO7 compound is chemically distinct from narcotic compounds, as it provides targeted cough suppression without carrying the risks of dependence or generalized central nervous system depression.

What is the General Purpose and Form of Longatin?

The primary therapeutic purpose of Longatin is to provide symptomatic relief by reducing the frequency and intensity of a dry, nonproductive cough typically associated with minor respiratory irritations. Its mechanism involves inhibiting the cough reflex center in the brain's medulla, making it a centrally acting agent. Noscapine functions as a centrally acting cough suppressant with efficacy against nonproductive cough. This indicates that the effect is focused specifically on the neurological trigger for the cough. Longatin is manufactured for oral administration and is commonly supplied in multiple pharmaceutical preparations, including tablets, liquid solution, and syrup formulations, ensuring flexible administration for relief from irritating coughs.

Regulatory References

What side effects are possible with Longatin?

Possible side effects and safety information

The official documentation of Noscapine's safety profile focuses on the spectrum of observed adverse effects and known hypersensitivity risks, as classified by regulatory authorities. The reported effects are typically categorized by the physiological systems they affect.

Officially Documented Adverse Reactions

The safety documentation includes high-level adverse reactions across several System-Organ Classes. Effects pertaining to Nervous System disorders may include drowsiness, lightheadedness, and headache. Reactions affecting the Gastrointestinal System include nausea and abdominal pain. Furthermore, documented effects on the Cardiac system have included reports of chest pain.

System-Organ Class	Examples of Documented Effects
Nervous System	Drowsiness, Lightheadedness, Headache
Gastrointestinal System	Nausea, Abdominal pain

Serious Safety Concerns and Contraindication

The most clinically significant safety pattern documented involves Immune System disorders presenting as hypersensitivity reactions. Documented serious manifestations have included angioedema (swelling of the face, lips, or throat) and laryngeal oedema, which can progress to respiratory failure. Such severe reactions define the primary restriction on use: known hypersensitivity to the active ingredient, Noscapine, is an explicit contraindication listed in the official Summary of Product Characteristics (SmPC) across various jurisdictions.

Contextual Safety Patterns

The temporal relationship of some adverse reactions has been characterized in pharmacovigilance data. The emergence of symptoms such as abdominal pain, chest pain, and headache often occurs within a few hours after intake, suggesting an acute onset. These specific symptoms were often observed to resolve without treatment after a few hours, indicating a transient profile for these reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

This section details the officially documented manifestations of Longatin (Noscapine) overdose and the specific emergency actions required, as mandated by government regulatory sources. Overdose presentations are classified by effects on major physiological systems.

Documented Overdose Manifestations

Manifestations of Noscapine overdose, particularly when intake significantly exceeds the recommended dosage, primarily involve the Central Nervous System (CNS) and Gastrointestinal systems.

System Affected	Documented Presentations
CNS	Drowsiness, confusion, agitation, seizures, and in severe cases, coma.
Gastrointestinal	Nausea and vomiting are commonly documented manifestations.
Severe Risk	Potential for respiratory failure and life-threatening hypersensitivity reactions, such as angioedema (swelling of the face or throat), is noted in regulatory summaries.

Mandated Emergency Response and Management

Any suspected overdose with Longatin requires immediate professional medical intervention.

Action Required: Seek immediate medical attention or call a doctor or Poison Information Center without delay upon suspicion of an overdose. The management strategy relies on supportive care.
Management Strategy: Management is strictly symptomatic and supportive therapy. No specific antidote is available or indicated for Noscapine overdose, requiring treatment to stabilize the patient and manage clinical signs.
Population Note: Official documents highlight elderly patients and children under 30 months as high-risk groups due to potential for increased sensitivity leading to the risk of respiratory failure.

Therapeutic Uses of Longatin

What Longatin Treats: Main Uses and Benefits

The primary therapeutic domain of Longatin is applied in addressing symptomatic relief of cough.

Symptomatic Relief and Functional Stability

Longatin is commonly used to help with the symptomatic relief of persistent, dry, and irritating coughs—those that do not produce phlegm. It helps address symptom clusters that interfere with daily comfort, such as the frequent, hacking cough associated with acute or episodic changes like colds or inhaled irritants. The key indications are associated with symptoms related to physical discomfort, symptoms related to inflammatory or irritative states, and symptoms that interfere with daily functioning.

“This is applied in addressing groups of symptoms that may become intense or disruptive, and is considered relevant in situations involving sudden or heightened symptomatic episodes.”

This provides support that helps ease the overall symptom burden, making the episodes easier to tolerate. This supports the overall management of the symptom burden, which contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Quick Fact: Supports management of Persistent Dry Cough

Regulatory References

Dextromethorphan: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Longatin?

This medicine's use is strictly governed by population eligibility rules found in official regulatory documents, which define who is permitted to use the drug, who is restricted, and who must not use it.

Eligibility Scope

Classification	Status	Affected Population
Absolute Contraindication	Must Not Use	Pregnant women; Patients with known hypersensitivity to Noscapine; Patients with severe respiratory depression; Children under 30 months old.
Conditional Restriction	Use with Caution	Patients with severe renal or hepatic impairment; Individuals with pre-existing heart, kidney, or lung diseases, hypertension, or diabetes.
Age Restriction	Not Recommended	Children under 2 years for non-prescription use, as no dosage is officially established except under medical advice.
Age Eligibility	Approved	Adults and Children 2 to 12 years and older, with age-appropriate dosage specified in the labeling.
Reproductive Status	Not Recommended	Lactation/Breastfeeding is generally not recommended as safety in this population has not been fully established.

Connection to the Overall Eligibility Profile

Regulatory documents define eligibility for Longatin by setting clear limitations across age, health status, and reproductive status. Use is prohibited in populations with absolute non-eligibility status, such as pregnant women and those with known hypersensitivity. Eligibility for other populations, including older adults or patients with organ or cardiovascular conditions, is conditional and requires explicit caution as noted in the official product information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Longatin (Noscapine) defines specific interaction patterns rooted in pharmacokinetic and pharmacodynamic mechanisms, strictly based on government-mandated labeling.

Interaction Scope and Restrictions

Longatin is contraindicated for co-administration with Monoamine Oxidase Inhibitors (MAOIs) due to the documented potential for serious or unknown adverse effects. No mandatory time separation rules are explicitly documented in the regulatory profile.

The primary pharmacokinetic interaction involves Longatin acting as an inhibitor of Cytochrome P450 enzymes, specifically CYP2C9 and CYP3A4. This enzyme inhibition is formally noted to reduce the clearance and increase the plasma concentration of co-administered medicines that are substrates for these metabolic pathways.

Clinically Significant Outcomes

The most clinically significant interaction is with oral anticoagulants (e.g., Warfarin), as this co-administration can lead to a significant increase in the International Normalized Ratio (INR), elevating the regulatory-documented risk of bleeding. The magnitude of this exposure increase is formally noted to be influenced by a patient's CYP2C9 genotype variants.

A pharmacodynamic interaction is documented with other Central Nervous System (CNS) depressants, including alcohol. Co-administration with these substances results in additive sedative effects, a condition specifically noted in official labeling.

Connection to the overall interaction profile

Regulatory documents define the product's interaction structure based on potent inhibition of CYP enzymes and the potential for additive CNS depression. This framework establishes the necessary constraints, including the formal contraindication with MAOIs and caution for CYP substrate co-administration.

Mechanism of Action

How Longatin Works

The pharmacological mechanism of Longatin (Noscapine) is defined by two primary, distinct domains of action: central receptor engagement and intracellular cytoskeletal modulation.

Modulation of Central Receptor Signaling

This domain involves engagement of sigma opioid receptors within the central nervous system. This molecular interaction initiates an alteration in signaling that affects the integration of efferent signals within the central cough center, modifying signaling sequences that regulate the degree of physiological response. The compound acts on sigma opioid receptors independently of mu opioid receptor binding.

Regulation of Cellular Microtubule Dynamics

The drug acts within domains involving non-receptor-mediated binding to the tubulin protein. This interaction modifies the polymerization state of tubulin within the cell's cytoskeleton, altering the stability and dynamics of cellular microtubules. This mechanism modifies early molecular steps dependent on the structural integrity and function of the cytoskeleton.

Dosage and Administration Information

How to Use Longatin

Longatin, which contains Noscapine, is administered via the oral route for its role as an antitussive, being primarily available in tablet and syrup or solution formulations. The proper use of this medicine is defined by specific dosing schedules and administration conditions.

Official Administration Guidelines

Instruction	Detail
Route of Administration	Oral administration only (tablets, syrup, solution).
Standard Adult Dose	Typically ranges from 50 mg to 100 mg per dose.
Dosing Frequency	Administered three to four times daily (TID to QID) as needed for cough symptom management.
Administration Timing	It is generally advised to take the medicine approximately one hour before meals (on an empty stomach).
Course Duration	The usage is designed for short-term duration. Consultation is generally advised if the cough persists for more than 14 days.

Procedural and Population-Specific Rules

For liquid preparations, such as the syrup or solution, the use of a calibrated measuring device is required to ensure dosage accuracy, rather than household utensils. This is a critical step in preventing unintentional dosing errors.

In the event of a missed dose, the procedural rule is to take the dose when remembered, unless it is nearly time for the next scheduled dose; it is specified not to double the dose to compensate.

Dose adjustments are a necessary consideration for specific groups. The dose for pediatric patients is adjusted based on age or weight. Furthermore, the drug must be used with caution in patients with severe renal or hepatic impairment, as these conditions can impact the drug's clearance, which necessitates a review of the dosage by a healthcare provider. Adherence to the stated dosage limit is mandatory across all populations.

Recent Clinical Evidence

Longatin: Recent Clinical Evidence

The Research Landscape for Dry Cough Relief

Longatin, which contains the active ingredient Noscapine, was studied in research examining its use as a non-narcotic agent for outcomes related to cough symptoms. The evidence landscape includes randomized controlled trials (RCTs), where Noscapine was compared against a placebo or other historical antitussive agents, alongside a broader body of peer-reviewed scientific studies. This research examined outcomes related to physical discomfort and changes in cough patterns over defined time intervals. Research explored the frequency and intensity of a persistent dry cough, which are outcomes reflecting daily functioning or activity level.

Evidence for Symptomatic Relief of Nonproductive Cough

The core research was studied for its use in outcomes related to acute or chronic dry, nonproductive cough. Studies focused on outcomes describing episodic or acute changes in cough symptoms. Researchers monitored changes in cough frequency and severity using both objective counts and patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies where outcomes related to cough frequency were observed in some studies to change during the short-term study periods. While recent controlled trials research examined symptoms in patients with acute cough, some of this data was studied for Noscapine when used in combination with other natural ingredients, limiting the precise insight into the single compound’s effect.

Research Gaps and Unanswered Questions

The quality of this evidence base varies across studies. Historically, some regulatory reviews have noted a reliance on older subjective studies in the evidence record. Data for certain groups remain insufficient, particularly for comprehensive pediatric studies that would establish age-appropriate profiles. Furthermore, because subgroup data remain insufficient, understanding why results may appear mixed across different clinical settings remains an active area of research discussion. The available evidence focuses on responses over defined time intervals; consequently, long-term effects are not fully established, and there is limited information for long-term outcomes regarding the sustained durability of relief.

Frequently Asked Questions (FAQ)

Common questions about Longatin (FAQ)

Q: Can Longatin be taken with food, or should it be on an empty stomach?

A: Official administration advice often states that Longatin should be taken approximately one hour before meals, which aligns with administration on an empty stomach. This is the primary instruction noted in official product information. Consulting with a healthcare provider can provide specific guidance regarding timing.

Q: Does Longatin have a risk of dependence or addiction?

A: Regulatory classifications describe Longatin (Noscapine) as a non-narcotic antitussive. This means the compound is chemically distinct from narcotic medications. Official safety profiles and classifications state that it is not associated with the risks of dependence or addiction that are inherent to narcotic-based compounds.

Q: Are there any known interactions between Longatin and alcohol?

A: Regulatory documents define a specific interaction with alcohol and other Central Nervous System (CNS) depressants. Co-administration can lead to an additive sedative effect, meaning both substances contribute to feelings of drowsiness. Regulatory warnings note the need for caution when using Longatin in combination with alcohol.

Q: Is it safe to drive or operate machinery while taking Longatin?

A: The official product information includes warnings about the potential for adverse effects such as drowsiness and sedation. Because of these potential effects, official product information notes the potential for these effects on ability to drive or operate machinery.

Q: How does Longatin compare to immediate-release versions of the same medicine?

A: Longatin is often manufactured as a sustained-release preparation. This formulation is designed to provide the effect of the medicine over an extended period. Immediate-release forms work more quickly but have a shorter duration of effect, which accounts for the difference in how they are used.

Q: Can I crush or chew Longatin tablets?

A: Regulatory instructions generally advise against modifying the tablet form of Longatin. Because it is manufactured as a sustained-release medicine, crushing, chewing, or breaking the tablet is explicitly advised against in official instructions. This is a necessary procedural rule to maintain the medicine’s intended duration of effect.

Q: What is the recommended approach for discontinuing Longatin?

A: Longatin is intended for short-term use for temporary symptom relief. Official administration guidance advises that if the cough persists for more than 14 days, the use of the medicine should be reviewed. There are no specific regulatory statements defining a mandatory tapering schedule for this short-term use.

Q: Can women who are breastfeeding use Longatin?

A: Regulatory documents state that Longatin is not recommended for women who are breastfeeding. This caution is noted because safety in this population has not been fully established, including whether the active substance might pass into breast milk.

Q: What if a person with kidney disease uses Longatin?

A: Official product information advises that Longatin must be used with caution in patients who have severe renal impairment (kidney disease). Because kidney function can impact how the body clears the medicine, and official information indicates a dosage review is a required consideration.

Q: How quickly can I expect Longatin to start working?

A: The exact onset of action—how quickly the medicine starts working—is not consistently defined across all regulatory labels. Some informational monographs may note that the time required for the medicine to show its action is not clinically established in a precise timeframe. Effects can vary among individuals.

Q: Are there any common over-the-counter medicines that interact with Longatin?

A: Regulatory documents list specific interactions with certain classes of medicines, such as oral anticoagulants and Monoamine Oxidase Inhibitors (MAOIs). There is also a general warning that the medicine may interact with a variety of other substances, indicating a need for caution when co-administering any medicines.

Q: Can people with liver problems use Longatin?

A: Regulatory documents advise that Longatin must be used with caution in patients with severe hepatic impairment (liver problems). Because the liver processes medicines, this condition may affect the body's ability to clear the drug, and official information indicates a review of use is a required consideration.

Q: Are there different strengths of Longatin available?

A: Yes, official regulatory labels and product information documents specify that the medicine is manufactured and supplied in different strengths. These variations are available for both the tablet formulation and the liquid formulations (syrup or solution).

Q: Is Longatin effective for all types of pain?

A: Official regulatory documents classify Longatin as a non-narcotic antitussive. It is formally indicated only for the symptomatic relief of dry, nonproductive cough. It is not officially indicated or studied for use in the relief of pain.

Q: Does Longatin interact with common herbal supplements like St. John's Wort?

A: Regulatory documents advise caution for co-administration with other medicines and compounds. The official interaction profile notes that Longatin inhibits certain CYP enzymes. Because some herbal supplements, such as St. John's Wort, can also affect these enzymes, caution is noted regarding potential interactions.

Q: Are there any specific dietary restrictions when taking Longatin?

A: Regulatory documentation specifically addresses administration timing (advising use before meals) and the interaction with alcohol. Beyond alcohol, no other specific foods or dietary components are typically mandated for restriction in the official product information.

Q: Does the evidence for Longatin include studies in diverse populations?

A: Official regulatory assessments note that the evidence base varies across studies. Documents indicate that data for certain subgroups remain insufficient, particularly for comprehensive studies that would establish age-appropriate profiles for pediatric patients. Research continues to explore outcomes in various groups.

How should Longatin be stored and disposed of?

Official Storage and Disposal Requirements

Official labeling mandates that Longatin must be stored under controlled environmental conditions to maintain its chemical stability and quality. The product should be stored at temperatures below 30°C and must be kept in its original container.

Storage Conditions

Requirement	Condition
Temperature	Store below 30°C
Protection	Protect from light, heat, and moisture
Container	Keep tightly closed
Safety	Store out of the reach and sight of children

To prevent degradation, the container must be kept tightly closed and protected from light and moisture. Consistent with all pharmaceutical products, Longatin must be stored out of the reach and sight of children.

Disposal Instructions

Unused or expired Longatin must be disposed of in accordance with local, regional, and national regulations. To protect the environment, the product must not be released into drains, water courses, or the soil.

Longatin